Search

Your search keyword '"Tahara M"' showing total 1,289 results

Search Constraints

Start Over You searched for: Author "Tahara M" Remove constraint Author: "Tahara M"
1,289 results on '"Tahara M"'

Search Results

5. Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

6. Health-Related Quality of Life (HRQoL) Data From KEYNOTE-412: Chemoradiotherapy (CRT) with or Without Pembrolizumab (pembro) in Patients (pts) with Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

7. Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study

8. Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study

9. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

10. Global structure of isothermal X-ray emission along the Fermi bubbles

11. Fermi-LAT and Multi-wavelength Monitoring of the Broad Line Radio Galaxy 3C 120

12. Suzaku X-ray Observations of the Fermi Bubbles: Northernmost Cap and Southeast Claw Discovered with MAXI-SSC

13. Six Years of Fermi-LAT and Multi-wavelength Monitoring of the Broad-Line Radio Galaxy 3C 120: Jet Dissipation at Sub-parsec Scales from the Central Engine

14. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

15. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial †

16. 106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study

17. Suzaku observations of the diffuse x-ray emission across the fermi bubbles' edges

18. Multiband Diagnostics of Unidentified 1FGL Sources with Suzaku and Swift X-ray Observations

28. 222O Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours

29. LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

30. 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048

31. 667P Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours

32. 520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358

35. 851MO Final analysis of a phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck (JCOG1008)

39. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

40. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

41. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

42. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.

45. Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy

46. A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36)

47. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

Catalog

Books, media, physical & digital resources